PTSD

When I started MAPS in 1986, the FDA was still blocking all research with psychedelics. MAPS had to try, though we might never succeed, to gather sufficient data about the safety and efficacy of MDMA-assisted …

The stakes were high: This was the final phase — phase 3 — of MAPS’s study aiming to convince the FDA to approve MDMA-assisted therapy for PTSD. Doblin knew that if the participants didn’t see …